MEDICIS-PROMED is a network that bridges different disciplines across fundamental research institutions, private companies and hospitals for the production of innovative medical isotopes and radiopharmaceuticals for the imaging and therapy of cancer. Radioisotopes are commonly used for functional imaging and are expected to play an enhanced role in treatment of various types of cancer.
At CERN a new facility is under construction, named MEDICIS, which will provide dedicated medical batches for radiopharmaceuticals and develop new accelerator technologies for medical applications. It will extend the capabilities of the ISOLDE radioactive ion beam facility, operated with a 1.4 GeV proton beam and the on-line mass separator, which allows the production of a spread variety of radioisotopes for different aims.
MEDICIS-PROMED is a Marie Sklodowska-Curie innovative training network of the Horizon 2020 European Commission`s program. Outcome of this network will be a new generation of entrepreneurial scientists, who will take advantage of the different interdisciplinary fields, in order to develop medical systems for new personalized medicine and to develop a network of experts within Europe. The EU support consists of 15 PhD projects based in different partner sites all over the Europe, which are coordinated by CERN. MEDICIS-PROMED is a wide project that covers all aspects from the radioisotope production to the medical application passing through the collection, shipment, safety control and the radiochemical synthesis. The project started in April 2015 and will end in 2019. Together with the completion of the MEDICIS facility (2017), MEDICIS-PROMED will reach its full speed.